Interferon γ-independent rejection of interleukin 12-transduced carcinoma cells requires CD4+ T cells and granulocyte/macrophage colony- stimulating factor

Journal of Experimental Medicine

Volumn 188, Issue 1, 1998, Pages 133-143

  Zilocchi, Chiara ^a   Stoppacciaro, Antonella ^b   Chiodoni, Claudia ^a   Parenza, Mariella ^a   Terrazzini, Nadia ^a   Colombo, Mario P ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

CD4T lymphocytes; Interferon ; Interleukin 12; Knockout mice; Tumor immunity

Indexed keywords

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOLOGY; COLON CARCINOMA; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; IMMUNOREACTIVITY; INTERFERON PRODUCTION; MALE; MEMORY CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR VASCULARIZATION;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL TRANSFORMATION, NEOPLASTIC; CHEMOKINES, CXC; COLONIC NEOPLASMS; CYTOTOXICITY, IMMUNOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INTERFERON TYPE II; INTERLEUKIN-12; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; NEOPLASMS, EXPERIMENTAL; NITRITES; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 0032490564     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.188.1.133     Document Type: Article

References (43)

1. Trinchieri, G. 1995. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridges innate resistance and antigen-specific adaptive immunity. Annu. Rev. Immunol. 13:251-276.
2. Brunda, M.J., L. Luistro, R.R. Warner, R.B. Wright, B.R. Hubbard, M. Murphy, S.F. Wolf, and M.K. Gately. 1993. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J. Exp. Med. 178:1223-1230.
3. Zou, J.-P., N. Yamamoto, T. Fujii, H. Takenaka, M. Kobayashi, S.H. Herrmann, S.F. Wolf, H. Fujiwara, and T. Hamaoka. 1995. Systemic administration of rIL-12 induces complete tumor regression and protective immunity: response is correlated with a striking reversal of suppressed IFNγ production by anti-tumor T cells. Int. Immunol. 7: 1135-1145.
4. Tannenbaum, C.S., N. Wicker, D. Armstrong, R. Tubbs, J. Finke, R.M. Bukowski, and T.A. Hamilton. 1996. Cytokine and chemokine expression in tumors of mice receiving systemic therapy with IL-12. J. Immunol. 156:693-699.
5. Angiolillo, A.L., C. Sgadari, D.D. Taub, F. Liao, J.M. Farber, S. Maheshwari, H.K. Kleinman, G.H. Reaman, and G. Tosato. 1995. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J. Exp. Med. 182:155-162.
6. Luster, A.D., S.M. Greenberg, and P. Leder. 1995. The IP-10 chemokine binds to a specific cell surface heparan sulfate site shared with platelet factor 4 and inhibits endothelial cell proliferation. J. Exp. Med. 182:219-231.
7. Brunda, M.J., L. Luistro, J.A. Hendrzak, M. Fountoulakis, G. Garotta, and M.K. Gately. 1995. Role of IFNγ in mediating the antitumor efficacy of interleukin-12. J. Immunother. 17: 71-77.
8. Presky, D.H., U. Gubler, R.A. Chizzonite, and M.K. Gately. 1995. IL-12 receptors and receptor antagonists. Res. Immunol. 146:439-445.
9. Trembleau, S., T. Germann, M.K. Gately, and L. Adorini. 1995. The role of IL-12 in the induction of organ-specific autoimniune diseases. Immunol. Today. 16:383-386.
10. Hultgren, B., X. Huang, N. Dybdal, and T.A. Stewart. 1996. Genetic absence of gamma-interferon delays but does not prevent diabetes in NOD mice. Diabetes. 45:812-817.
11. Martinotti, A., A. Stoppacciaro, M. Vagliani, C. Melani, F. Spreafico, M. Wysocka, G. Parmiani, G. Trinchieri, and M.P. Colombo. 1995. CD4 T cells inhibits in vivo the CD8-mediated immune response against murine colon carcinoma cells transduced with IL-12 genes. Eur. J. Immunol. 25:137-146.
12. Colombo, M.P., M. Vagliani, F. Spreafico, M. Parenza, C. Chiodoni, C. Melani, and A. Stoppacciaro. 1996. The amount of IL-12 available at the tumor site is critical for tumor regression. Cancer Res. 56:2531-2534.
13. Corbett, T.H., D.P. Griswold, Jr., B.J. Roberts, J.C. Peckham, and F.M. Schabel, Jr. 1975. Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assay, with a note on carcinogen structure. Cancer Res. 35:2434-2437.
14. Dalton, D.K., S. Pitts-Meek, S. Keshav, I.S. Figari, A. Bradlev, and T.A. Stewart. 1993. Multiple defects of immune cell function in mice with disrupted interteron-γ genes. Science. 259:1739-1745.
15. Stoppacciaro, A., C. Melani, M. Parenza, A. Mastracchio, C. Bassi, C. Baroni, G. Parmiani, and M.P. Colombo. 1993. Regression of an established tumor genetically modified to release granulocyte colony-stimulating factor requires granulocyte-T cell cooperation and T cell-produced interteron γ. J. Exp. Med. 178:151-161.
16. Huang, A.S., P.H. Gulden, A.S. Woods, M.C. Thomas, C.D. Tong, W. Wang, V.H. Engelhard, G. Pasternack, R. Cotter, D. Hunt, et al. 1996. The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. Proc. Natl. Acad. Sci. USA. 93:9730-9734.
17. Ding, A.H., C.F. Nathan, and D.J. Stuehr. 1988. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages: comparison of activating cytokines and evidence for independent production. J. Immunol. 141:2407-2412.
18. Colombo, M.P., and G. Forni. 1994. Cytokine gene transfer in tumor inhibition and tentative tumor therapy: where are we now? Immunol. Today. 15:48-51.
19. Rodolfo, M., C. Castelli, C. Bassi, P. Accornero, M. Sensi, and G. Parmiani. 1994. Cytotoxic T lymphocytes recognize tumor antigens of a murine colonic carcinoma by using different T-cell receptors. Int. J. Cancer. 57:440-147.
20. Wigginton, J.M., D.H. Kuhns, T.C. Back, M.J. Brunda, R.H. Wiltrout, and G.W. Cox. 1996. Interleukin 12 primes macrophages for nitric oxide production in vivo and restores depressed nitric oxide production by macrophages from tumor-bearing mice: implications for the antitumor activity of interleukin 12 and/or interleukin 2. Cancer Res. 56:1131-1136.
21. Voest, E.E., B.M. Kenyon, M.S. O'Reilly, G. Truitt, R.J. D'Amato, and J. Folkman. 1995. Inhibition of angiogenesis in vivo by interleukin 12. J. Natl. Cancer Inst. 87:581-586.
22. Brooks, P.C., R.A.F. Clark, and D.A. Cheresh. 1994. Requirement of vascular integrin αvβ3 for angiogenesis. Science. 264:569-571.
23. Cavallo, F., P. Signorelli, M. Giovarelli, P. Musiani, A. Modesti, M.J. Brunda, M.P. Colombo, and G. Forni. 1997. Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12. J. Natl. Cancer Inst. 89:1049-1058.
24. Nastala, C.L., H.D. Edington, T.G. McKinney, H. Tahara, M.A. Nalesnik, M.J. Brunda, M.K. Gately, S.F. Wolf, R.D. Schreiber, W.J. Storkus, and M.T. Lotze. 1994. Recombinant IL-12 administration induces tumor regression in association with IFNγ production. J. Immunol. 153:1697-1706.
25. Rodolfo, M., C. Zilocchi, C. Melani, B. Cappetti, I. Arioli, G. Parmiani, and M.P. Colombo. 1996. Immunotherapy of experimental metastases by vaccination with interleukin gene-transduced adenocarcinoma cells sharing tumor-associated antigens. Comparison between IL-12 and IL-2 gene-transduced tumor cell vaccines. J. Immunol. 157:5536-5542.
26. Vagliani, M., M. Rodolfo, F. Cavallo, M. Parenza, C. Melani, G. Parmiani, G. Forni, and M.P. Colombo. 1996. IL-12 potentiates the curative effect of a vaccine based on IL-2 transduced tumor cells. Cancer Res. 56:467-170.
27. + tumor-infiltrating lymphocytes. J. Exp. Med. 173:647-653.
28. Nathan, C., and M.J. Sporn. 1991. Cytokines in the context. J. Cell Biol. 113:981-985.
29. Musiani, P., A. Allione, A. Modica, P.L. Lollini, M. Giovarelli, F. Cavallo, F. Belardelli, G. Forni, and A. Modesti. 1996. Role of neutrophils and lymphocytes in inhibition of a mouse mammary adenocarcinoma engineered to release IL-2, IL-4, IL-7, IL-10, IFN-alpha, IFN-gamma, and TNF-alpha. Lab. Invest. 74:146-157.
30. Locksley, R.M. 1993. Interleukin 12 in host defense against microbial pathogens. Proc. Natl. Acad. Sci. USA. 90:5879-5880.
31. Harty, J.T., and M.J. Bevan. 1995. Specific immunity to Listeria monocytogenes in the absence of IFNγ. Immunity. 3:109-117.
32. Wang, Z.-E., S. Zheng, D.B. Corry, D.K. Dalton, R.A. Seder, S.L. Reiner, and R.M. Locksley. 1994. Interteron γ-independent effects of interleukin 12 administered during acute or established infection due to Leishmania major. Proc. Natl. Acad. Sci. USA. 91:12932-12936.
33. Szabo, S.J., A.S. Dighe, U. Gubler, and K.M. Murphy. 1997. Regulation of the interleukin (IL)-12Rb2 subunit expression in developing T helper 1 (Th1) and Th2 cells. J. Exp. Med. 185:817-824.
34. Cavallo, F., M. Giovarelli, A. Gulino, A. Vacca, A. Stoppacciaro, A. Modesti, and G. Forni. 1992. Role of neutrophils and CD4+ T lymphocytes in the primary and memory response to nonimmunogenic murine mammary adenocarcinoma made immunogenic by IL-2 gene transfection. J. Immunol. 149:3627-3635.
35. Musiani, P., A. Modesti, M. Giovarelli, F. Cavallo, M.P. Colombo, P.L. Lollini, and G. Forni. 1997. Cytokines, tumor-cell death and immunogenicity: a question of choice. Immunol. Today. 18:32-36.
36. Schwartzentruber, D.J., S.S. Hom, M. Dadmarz, D.E. White, J.R. Yannelli, S.M. Steinberg, S.A. Rosenberg, and S.L. Topalian. 1994. In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2. J. Clin. Oncol. 12:1475-1482.
37. Ginsburg, I., D.F. Gibbs, and J. Varani. 1989. Interaction of mammalian cells with polymorphonuclear leukocytes: relative sensitivity to monolayer disruption and killing. Inflammation. 13:529-542.
38. Perussia, B., M. Kobayashi, M.E. Rossi, I. Anegon, and G. Trinchieri. 1987. Immune interferon enhances functional properties of human granulocytes: role of Fc receptors and effect of lymphotoxin, tumor necrosis factor, and granulocyte-macrophage colony-stimulating factor. J. Immunol. 138: 765-773.
39. Taylor, A.P., and H.W. Murray. 1997. Intracellular antimicrobial activity in the absence of interferon-γ: effect of interleukin-12 in experimental visceral leishmaniasis in interteron-γ gene-disrupted mice. J. Exp. Med. 185:1231-1239.
40. Colombo, M.P., A. Modesti, G. Parmiani, and G. Forni. 1992. Local cytokine availability elicits tumor rejection and systemic immunity through granulocyte-T-lymphocyte cross-talk. Cancer Res. 52:4853-4857.
41. Luster, A.D., and P. Leder. 1993. IP-10, a -C-X-C-chemokine, elicits a potent thymus-dependent antitumor response in vivo. J. Exp. Med. 178:1057-1065.
42. Sgadari, C., A.L. Angiolillo, and G. Tosatto. 1996. Inhibition of angiogenesis by interleukin-12 is mediated by interferon-inducible protein 10. Blood. 87:3877-3882.
43. Westling, W.F., and M.A. Gimbrone. 1993. Neutrophil-mediated damage to human vascular endothelium. Role of cytokine activation. Am. J. Pathol. 142:117-128.